Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
about
Review: Hypertension, a health economics perspectiveEvidence-based prescribing of statins: a developing world perspective.Coronary heart disease policy models: a systematic reviewThe future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China.Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors.The association of low serum cholesterol with depression and suicidal behaviours: new hypotheses for the missing link.Mad cow disease. An opportunity for preventive medicine?RCT of a care manager intervention for major depression in primary care: 2-year costs for patients with physical vs psychological complaints.Cost-effectiveness of enhancing primary care depression management on an ongoing basis.Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions.Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and MedicineA cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation.Cost effectiveness of statins in coronary heart disease.Myocardial perfusion scintigraphy: the evidence.Myocardial perfusion scintigraphy and cost effectiveness of diagnosis and management of coronary heart diseaseLipid intervention trials in primary prevention: a critical review.Preventive medicine in the older patient: a United kingdom perspective.Decision models for assessing the cost effectiveness of drug-eluting stents.Use of recommended medications after myocardial infarction in AustriaDo doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment studyThe relative merits of population-based and targeted prevention strategiesFrom 4S to IDEAL: the health economics of the statin trials.Cost effectiveness of a government supported policy strategy to decrease sodium intake: global analysis across 183 nations.Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia.Cost-effectiveness of statins revisited: lessons learned about the value of innovation.Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.Life expectancy biases in clinical decision modeling.Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension.Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.The practical impact of pharmacoeconomics on institutional managers.Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users.Cost-effective strategies for the management of vascular disease.Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD.Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.Milton Weinstein's insights on the development, use, and methodologic problems in cost-effectiveness analysis.Do different methods of modeling statin treatment effectiveness influence the optimal decision?Preventive versus Curative Medicine: A Policy Exercise for the Classroom
P2860
Q22299226-7459EFF0-9A7B-43CB-B8E8-3B21E3FAD54EQ25255887-D4A6C346-22B2-48C1-8F73-53ED01559399Q28200183-A5E388FB-0F65-426B-AF73-1A88D961BD55Q33387452-5305A059-BAC5-4EAD-AB68-0FD70FA82FB3Q33631450-76424BBD-C077-45C5-B103-45F2478ED33BQ33846075-B62B67FA-1F6B-425E-A1A3-32D3A2FE14DDQ34146972-6BC5701D-F24C-4709-A687-1701DA8EB1A9Q34187504-C1D4509F-2476-4840-9567-DABBA88B9830Q34312666-C3303C81-FB3A-4424-91E1-3AF782D78531Q34312672-A12EC02A-B8C6-4067-9EB9-E71893405F6AQ34389584-3EAE2116-0E28-4815-8D9A-0812C58E9097Q34753553-0250503E-1576-45D9-AE87-7FDFC2491FB6Q35048588-B4B4E5F1-2ED3-46CA-AACE-C21996C23B55Q35417723-7408A487-4422-4EAB-9255-4C477A83C11BQ35765832-76ED8BA3-134C-4DFE-9F29-E80092496C22Q35808204-7F55386D-68C7-4B69-ABD6-21AC1193F192Q35898718-6EF40BFE-D7F2-4DA4-B97C-546FA8DB3792Q36075322-99E38688-684A-4FFE-ACB2-07B819371F9CQ36161276-DFF5C8B7-E0E9-47DF-820A-8B0BC261F8B1Q36473684-41CFF853-0E27-4CE5-9E61-0A981CC5553AQ36903173-F51A9CAB-D81B-4C05-866C-663CC7E0153BQ37212186-EE3D1EC8-9A72-4F74-AD9B-CCE57278FC36Q37451199-A3234EFF-B4B7-401D-A69A-D3002EF3DB81Q37578449-589FF0C5-AA6F-4FF2-A3B1-63B8E0050681Q37609307-30853763-520F-48AE-B344-EF76DB55FF52Q37870094-6F404FDF-F23A-4FFB-A152-A0ED5A553729Q38549355-CF6FFE0F-30AA-4D21-AC4B-F410CF5F97BDQ40546390-9DD5D033-A3F0-4CE6-916B-72907CC567DBQ40880167-AA80E131-DAF1-4EF5-B564-1E633AB7B74BQ40921761-B04E5C94-0013-4005-9713-AF0CC524BB1EQ41018882-01881489-B35D-44B3-B88E-EBCA00D2A26EQ41210727-4AE0B0EC-57AC-465A-8D12-40479D12FA79Q41650208-7FF7F2AB-754F-4287-BF2D-B2CBDEC18335Q41740403-ADD47A0A-21DF-4842-AFD2-1F67AB413F37Q43266394-23BA9CBA-38EF-4DBE-B658-98137D311B57Q45237334-20CA9906-E0CA-4D3D-8C42-9026F669D891Q45237338-10EE8303-F1B0-4106-8660-FF9EF28557A9Q50268109-C62A136B-2193-4372-A925-D44B057C7FDFQ51388742-B34CB1BA-5F34-4021-B251-06BF0C887D83Q58546464-F2C90EF1-182F-46D8-B8CE-2D6EDADD2812
P2860
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Cost-effectiveness of HMG-CoA ...... ion of coronary heart disease.
@en
Cost-effectiveness of HMG-CoA ...... ion of coronary heart disease.
@nl
type
label
Cost-effectiveness of HMG-CoA ...... ion of coronary heart disease.
@en
Cost-effectiveness of HMG-CoA ...... ion of coronary heart disease.
@nl
prefLabel
Cost-effectiveness of HMG-CoA ...... ion of coronary heart disease.
@en
Cost-effectiveness of HMG-CoA ...... ion of coronary heart disease.
@nl
P2093
P1476
Cost-effectiveness of HMG-CoA ...... ion of coronary heart disease.
@en
P2093
L W Williams
M C Weinstein
P A Goldman
P304
P356
10.1001/JAMA.1991.03460090093039
P407
P577
1991-03-01T00:00:00Z